A5027849110- Health Systems, Economic Evaluations, Quality of Life
- Psoriasis: Treatment and Pathogenesis
- CAR-T cell therapy research
- Economic and Financial Impacts of Cancer
- Global Cancer Incidence and Screening
- Biosimilars and Bioanalytical Methods
- Pneumocystis jirovecii pneumonia detection and treatment
- Integrated Circuits and Semiconductor Failure Analysis
- Atrial Fibrillation Management and Outcomes
- Meta-analysis and systematic reviews
- Parallel Computing and Optimization Techniques
- Lymphoma Diagnosis and Treatment
- Ovarian cancer diagnosis and treatment
- Health and Medical Research Impacts
- Cancer Diagnosis and Treatment
- Lung Cancer Diagnosis and Treatment
- Antiplatelet Therapy and Cardiovascular Diseases
- Inflammatory Bowel Disease
- Acute Myeloid Leukemia Research
- Colorectal Cancer Screening and Detection
- Advanced Causal Inference Techniques
- Tensor decomposition and applications
- Acute Lymphoblastic Leukemia research
- Electrolyte and hormonal disorders
- Myeloproliferative Neoplasms: Diagnosis and Treatment
Evidence Based Research (United States)
2024
University of Washington
2016-2023
Open Evidence
2023
Access to Wholistic and Productive Living Institute
2023
Open Health Systems Laboratory
2021-2022
Pharmerit (United States)
2021
National Taiwan University of Science and Technology
2019
Here, we report the first comparative analysis of patient-reported outcomes (PROs) with chimeric antigen receptor T-cell therapy vs standard-of-care (SOC) in second-line relapsed/refractory large B-cell lymphoma (R/R LBCL) from pivotal randomized phase 3 ZUMA-7 study axicabtagene ciloleucel (axi-cel) SOC. PRO instruments were administered at baseline, day 50, 100, 150, month 9, and every months randomization until 24 or an event-free survival event. The quality life (QoL) set comprised...
Deucravacitinib, an oral tyrosine kinase 2 (TYK2) inhibitor, is approved in the United States to treat adults with moderate-to-severe plaque psoriasis (PsO). This study compared long-term efficacies of deucravacitinib and adalimumab using results from extension (LTE) trials. Open-label LTE trials were identified for indirect treatment comparison (deucravacitinib: POETYK PSO-LTE [NCT04036435]; adalimumab: REVEAL [NCT00195676]). To ensure design comparability, patients initially randomized...
Abstract Aims The Cardiovascular Outcomes for People Using Anticoagulation Strategies (COMPASS) trial demonstrated that rivaroxaban 2.5 mg BID with aspirin 100 was more effective than daily alone the prevention of cardiovascular (CV) death, stroke, or myocardial infarction in patients stable coronary artery disease (CAD) peripheral (PAD). We aimed to examine cost-effectiveness using patient-level data from COMPASS trial. Methods and results performed an in-trial analysis extrapolated our 33...
African American men have a higher burden of prostate cancer compared with other populations. We sought to determine if they experience disparities in access clinical trials.We created database all US counties by linking trial data county-level socioeconomic, demographic, and health-care facility derived from several external sources. Using this linkage, we examined 2 potential barriers. investigated the relationship between proportion Americans facilities, adjusting for county population...
Abstract Objectives: Evidence on the comparison of treatments for hepatorenal syndrome-acute kidney injury (HRS-AKI) in a US population is limited. An indirect terlipressin plus albumin versus midodrine and octreotide (MO) may provide further insight into treatment efficacy. Methods: Cohorts patients treated HRS-AKI characterized by serum creatinine [SCr] < 5 mg/dL, baseline acute-on-chronic liver failure (ACLF) grades 0-2, exclusion listed transplant if MELD ≥ 35 were pooled from 1)...
Rivaroxaban 2.5 mg twice daily with aspirin 100 was shown to be better than for preventing cardiovascular (CV) death, stroke or myocardial infarction in patients either stable coronary artery disease (CAD) peripheral (PAD). The cost-effectiveness of this regimen population is essential decision-makers know. US direct healthcare system costs (in USD) were applied hospitalized events, procedures and study drugs utilized by all patients. We determined the mean cost per participant full duration...
Aim: To evaluate the economic and humanistic burden of ovarian cancer in USA. Methods: Medical Expenditure Panel Survey data (2007-2018) were used to estimate all-cause healthcare resource use costs for examine activities daily living quality-of-life (QoL) measures between patients a non-cancer population. Results: Compared with controls, had more comorbidities worse QoL. Their predicted number annual hospitalizations office-based visits was significantly higher, as their estimated total...
Previous analyses using the SEER-Medicare database have reported substantial underutilization of hypomethylating agents (HMAs) among patients with higher-risk myelodysplastic syndromes (MDS), and an association between poor HMA persistence high economic burden. We aimed to compare rates hospitalizations emergency room (ER) visits MDS according use or non-use therapy, explore factors associated early discontinuation therapy.We used 2010-2016 identify aged ≥66 years a new diagnosis refractory...
Deucravacitinib demonstrated superior efficacy to apremilast in patients with moderate severe plaque psoriasis the POETYK PSO-1 and PSO-2 clinical trials. In study reported here, we aimed determine overall 52-week cumulative benefit of treatment initiated deucravacitinib versus compare initiating staying on continuing or switching at week 24 treatment. This post hoc analysis data (ClinicalTrials.gov identifier: NCT03624127) determined 6 mg once daily 30 twice adults psoriasis. Patients...
To explore whether investments in translational sciences for six metastatic cancers follow idiosyncratic returns to those rather than levels of burden illness (BI).Associate the number clinical trials USA involving oncolytic drugs approved during 2008-2013 and level (in 2008) changes (2002-2008 2008-2014) cancer-specific years life lost.Investments were positively associated only with contemporary BI (2008-2014). The relationship was stronger government-sponsored comparative-effectiveness...
7043 Background: Real-world studies have shown that persistence with intravenous (IV) and subcutaneous (SC) hypomethylating agents (HMAs) among patients (pts) higher-risk myelodysplastic syndromes (MDS) is poor, over one-third of treated pts receiving <4 cycles or having a ≥90-day gap in therapy, despite recommendations for at least 4-6 to elicit response absence progression/unacceptable toxicity. Survival outcomes also been be worse, direct medical costs higher, HMA non-persistent vs...
6553 Background: African American men (AAs) have a higher burden of prostate cancer compared to other populations. We sought determine if they experience disparities in access clinical trials. Methods: created county-level database all U.S. counties by linking together trial data from the Aggregate Analysis ClincalTrials.gov (AACT) with socioeconomic, demographic and healthcare facility derived several external sources. Using this linkage, we examined two specific potential barriers. First,...
Introduction: Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 (TYK2) inhibitor, is approved in the US for treatment of adults with moderate to severe plaque psoriasis (PsO). A previous indirect study showed comparable efficacy between deucravacitinib and first-generation biologics at week 52. The objective this was compare long-term that adalimumab based on extension (LTE) trials, after adjusting differences patient characteristics baseline. 
 Methods: Open-label LTE...
6515 Background: Access to and patient enrollment in cancer clinical trials is likely strongly impacted by where trial sites are located. Our objective was evaluate temporal trends the geographic location of launched US. Methods: We obtained recruiting location(s) all public- privately-funded phase II/ III US between 2008 2015 from ClinicalTrials.gov database. linked each relevant hospital service area (HSA), which defined ZIP codes as local health care markets for (n = 3436). estimated...
Meta-analyzing count data can be challenging when follow-up time varies across studies. Simply pooling aggregate over time-periods would result in biased estimates, which may erroneously inform clinical decision-making. In this study, we exploit the convolution property of Poisson distribution to develop a likelihood for observed cumulative counts varying periods, where different distributions are used represent generating processes latent pre-defined successive intervals follow-up. We...